Drotrecogin alfa (activated): real-life use and outcomes for the UK

INTRODUCTION: In March 2001, the results of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study were published, which indicated a 6.1% absolute reduction in 28-day mortality. Drotrecogin alfa (activated; DrotAA) was subsequently approved for use in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowan, Kathryn M, Welch, Catherine A, North, Emma, Harrison, David A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447613/
https://www.ncbi.nlm.nih.gov/pubmed/18430215
http://dx.doi.org/10.1186/cc6879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447613/
https://www.ncbi.nlm.nih.gov/pubmed/18430215
http://dx.doi.org/10.1186/cc6879

Ejemplares similares